Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States.

Reginster JY, Silverman SL, Alokail M, Al-Daghri N, Hiligsmann M

JBMR plus6 Nov 2024Cited by 8 (Europe PMC)

PMID39664931PMCIDPMC11631096DOI10.1093/jbmrpl/ziae138PepBankPUB-39664931

Summary

Radiofrequency echographic multi-spectrometry (REMS) is an innovative, non-ionizing diagnostic technique that has shown high accuracy and precision, making it a promising alternative to DXA for osteoporosis diagnosis in clinical settings. With economic considerations playing an increasingly crucial role in healthcare decisions, this study aims to evaluate the cost-effectiveness and economic impact of improved osteoporosis diagnosis using REMS followed by treatment in the United States. A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis. Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate). The study evaluated 2 medication adherence scenarios: one assuming full adherence to treatment and the other reflecting real-world adherence. The results indicate that REMS followed by treatment is associated with improved health outcomes, including more QALYs and fewer fractures, and reduced fracture-related costs compared to no diagnosis and treatment. The incremental cost-effectiveness ratio of REMS was estimated at $33 891 and $49 198 per QALY gained, under the full adherence and real-world adherence scenarios, respectively. These values are below the US cost-effectiveness threshold of $100 000 per QALY. Moreover, a 5% increase in the diagnosis and treatment of women over 50 yr at high and very high risk of fractures using REMS is projected to save approximately 30 000 life yr, 43 500 QALYs, and prevent 100 000 fractures over a lifetime under real-world medication adherence. In conclusion, this study suggests that REMS is a cost-effective strategy for the diagnosis and management of osteoporosis in US women, offering substantial potential economic benefits and improved health outcomes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

01Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women with osteoporosis, REMS diagnosis followed by treatment increased QALYs versus no diagnosis or treatment.
In plain wordsIn a computer model, REMS diagnosis and treatment increased quality-adjusted life years versus no diagnosis or treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseQuality-adjusted life years
Study
n: not reported in source
Comparator
No diagnosis and treatment
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The results indicate that REMS followed by treatment is associated with improved health outcomes, including more QALYs and fewer fractures, and reduced fracture-related costs compared to no diagnosis and treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493101
02Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women with osteoporosis, REMS diagnosis followed by treatment reduced fractures versus no diagnosis or treatment.
In plain wordsIn a computer model, REMS diagnosis and treatment reduced fractures versus no diagnosis or treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseFractures
Study
n: not reported in source
Comparator
No diagnosis and treatment
Outcome group
Bone and joint · Whole body
Source sentences
Summary
The results indicate that REMS followed by treatment is associated with improved health outcomes, including more QALYs and fewer fractures, and reduced fracture-related costs compared to no diagnosis and treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493102
03Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women with osteoporosis, REMS diagnosis followed by treatment reduced fracture-related costs versus no diagnosis or treatment.
In plain wordsIn a computer model, REMS diagnosis and treatment reduced fracture-related costs versus no diagnosis or treatment.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseFracture-related costs
Study
n: not reported in source
Comparator
No diagnosis and treatment
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The results indicate that REMS followed by treatment is associated with improved health outcomes, including more QALYs and fewer fractures, and reduced fracture-related costs compared to no diagnosis and treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493103
04Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women, REMS cost per QALY gained was $33 891 with full adherence and $49 198 with real-world adherence.
In plain wordsIn a computer model, REMS cost per QALY gained was $33 891 or $49 198, depending on adherence.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableIncremental cost-effectiveness ratio
Study
n: not reported in source
Comparator
No diagnosis and treatment
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
The incremental cost-effectiveness ratio of REMS was estimated at $33 891 and $49 198 per QALY gained, under the full adherence and real-world adherence scenarios, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493104
05Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women over 50 at high or very high fracture risk, 5% expanded REMS diagnosis and treatment could save approximately 30 000 life years over a lifetime under real-world adherence.
In plain wordsA model predicted 5% expanded REMS diagnosis and treatment could save approximately 30 000 life years over a lifetime under real-world adherence.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLife years saved with expanded diagnosis
Study
n: not reported in source
Outcome group
Mortality · Whole body
Source sentences
Summary
Moreover, a 5% increase in the diagnosis and treatment of women over 50 yr at high and very high risk of fractures using REMS is projected to save approximately 30 000 life yr, 43 500 QALYs, and prevent 100 000 fractures over a lifetime under real-world medication adherence.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493105
06Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women over 50 at high or very high fracture risk, 5% expanded REMS diagnosis and treatment could gain 43 500 quality-adjusted life years over a lifetime under real-world adherence.
In plain wordsA model predicted 5% expanded REMS diagnosis and treatment could gain 43 500 quality-adjusted life years over a lifetime under real-world adherence.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseQALYs gained with expanded diagnosis
Study
n: not reported in source
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Moreover, a 5% increase in the diagnosis and treatment of women over 50 yr at high and very high risk of fractures using REMS is projected to save approximately 30 000 life yr, 43 500 QALYs, and prevent 100 000 fractures over a lifetime under real-world medication adherence.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493106
07Computer modelNot a test of Abaloparatide (Tymlos) aloneIn silicoOther
In simulated US women over 50 at high or very high fracture risk, 5% expanded REMS diagnosis and treatment could prevent 100 000 fractures over a lifetime under real-world adherence.
In plain wordsA model predicted 5% expanded REMS diagnosis and treatment could prevent 100 000 fractures over a lifetime under real-world adherence.
Peptide
Abaloparatide (Tymlos)
Outcome
DecreaseFractures prevented with expanded diagnosis
Study
n: not reported in source
Outcome group
Bone and joint · Whole body
Source sentences
Summary
Moreover, a 5% increase in the diagnosis and treatment of women over 50 yr at high and very high risk of fractures using REMS is projected to save approximately 30 000 life yr, 43 500 QALYs, and prevent 100 000 fractures over a lifetime under real-world medication adherence.
2 context sentences(design, population, supporting numbers)
Summary · context
A microsimulation-based Markov model was constructed to estimate the cost per quality-adjusted life year (QALY) gained (in US$2022) for REMS followed by treatment vs no diagnosis and treatment in US women aged 50 yr and older with osteoporosis.
Summary · context
Women were categorized as high risk (receiving alendronate monotherapy for 5 yr) or very high risk (receiving an 18-mo course of anabolic treatment, abaloparatide, followed by 5 yr of alendronate).
In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).
Show in the study text Report a problemFND-3966493107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.